Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MFSD2A lentiviral vector is a gene therapy construct designed to deliver and express the Major Facilitator Superfamily Domain Containing 2A (MFSD2A) protein in target cells. MFSD2A is a specialized sodium-dependent transporter located at the blood-brain barrier (BBB) that is essential for the uptake of lysophosphatidylcholine (LPC)-bound omega-3 fatty acids, particularly docosahexaenoic acid (DHA), into the central nervous system. Mutations in the MFSD2A gene result in a rare autosomal recessive neurodevelopmental disorder characterized by primary microcephaly, severe intellectual disability, and spasticity. This lentiviral vector is primarily utilized as a research tool to investigate lipid transport mechanisms and blood-brain barrier integrity, but it also serves as a preclinical candidate for gene replacement therapy to restore DHA transport and support brain growth in affected individuals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MFSD2A lentiviral vector.